GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Getein Biotech 603387.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

8.45

-0.71%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥1.05bn

FY2016FY2025

Net income

CN¥220.7m

FY2016FY2025

Free cash flow

CN¥242.0m

FY2016FY2025

Shareholders' equity

CN¥2.75bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥1.05bnCN¥1.16bnCN¥1.37bnCN¥1.82bnCN¥1.40bnCN¥1.12bnCN¥968.2mCN¥686.2mCN¥488.6mCN¥369.1m
Gross profitCN¥734.0mCN¥790.4mCN¥889.5mCN¥1.15bnCN¥916.3mCN¥708.9mCN¥703.3mCN¥542.2mCN¥400.0mCN¥299.7m
Research and developmentCN¥157.4mCN¥181.2mCN¥218.0mCN¥223.2mCN¥163.4mCN¥119.1mCN¥104.7mCN¥80.6mCN¥54.0mCN¥39.3m
Operating incomeCN¥257.0mCN¥258.1mCN¥306.6mCN¥563.3mCN¥452.8mCN¥378.0mCN¥398.9mCN¥282.8mCN¥223.3mCN¥152.6m
Net incomeCN¥220.7mCN¥223.6mCN¥279.8mCN¥498.9mCN¥399.0mCN¥304.7mCN¥339.7mCN¥249.6mCN¥194.0mCN¥138.4m
Diluted earnings per share0.470.430.550.990.760.610.660.480.380.37

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥3.76bnCN¥3.71bnCN¥3.77bnCN¥3.68bnCN¥3.14bnCN¥2.70bnCN¥2.01bnCN¥1.57bnCN¥1.27bnCN¥434.1m
Cash and short-term investments—CN¥1.00bnCN¥936.2mCN¥1.16bnCN¥1.58bnCN¥1.40bnCN¥1.13bnCN¥145.4mCN¥301.0mCN¥26.3m
Total liabilitiesCN¥896.6mCN¥986.4mCN¥1.03bnCN¥1.01bnCN¥863.9mCN¥695.9mCN¥326.0mCN¥187.2mCN¥118.9mCN¥91.1m
Debt—CN¥577.2mCN¥644.0mCN¥591.0mCN¥496.5mCN¥384.8mCN¥95.0mCN¥31.2m——
Shareholders' equityCN¥2.75bnCN¥2.62bnCN¥2.56bnCN¥2.48bnCN¥2.11bnCN¥1.84bnCN¥1.62bnCN¥1.35bnCN¥1.14bnCN¥340.1m
Shares outstanding469m516m508m503m527m498m514m524m509m378m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥392.6mCN¥423.0mCN¥333.2mCN¥483.0mCN¥432.4mCN¥185.5mCN¥225.7mCN¥187.1mCN¥191.9mCN¥155.9m
Capital spending−CN¥150.6m−CN¥156.4m−CN¥258.1m−CN¥217.4m−CN¥179.6m−CN¥113.5m−CN¥124.8m−CN¥110.7m−CN¥61.4m−CN¥39.3m
Free cash flowCN¥242.0mCN¥266.6mCN¥75.1mCN¥265.5mCN¥252.8mCN¥71.9mCN¥100.9mCN¥76.4mCN¥130.6mCN¥116.6m
Dividends paid−CN¥103.2m−CN¥111.0m−CN¥219.4m−CN¥123.2m−CN¥93.2m−CN¥104.2m−CN¥76.3m−CN¥59.8m−CN¥68.2m−CN¥59.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥287.8mCN¥267.5mCN¥294.0mCN¥245.0mCN¥268.5mCN¥244.1mCN¥285.0mCN¥262.2m
Gross profitCN¥195.5mCN¥188.2mCN¥211.7mCN¥170.1mCN¥163.8mCN¥188.4mCN¥179.5mCN¥184.0m
Operating incomeCN¥74.7mCN¥83.7mCN¥101.9mCN¥53.1mCN¥44.2mCN¥69.2mCN¥27.3mCN¥37.3m
Net incomeCN¥108.0mCN¥76.3mCN¥60.1mCN¥51.7mCN¥44.5mCN¥64.3mCN¥21.4mCN¥28.6m
Diluted earnings per share0.230.160.130.110.090.140.040.06
Cash from operations———CN¥100.0mCN¥98.0mCN¥48.0m—CN¥102.0m
Capital spending−CN¥26.0m−CN¥31.0m−CN¥31.0m−CN¥34.0m−CN¥38.0m−CN¥46.0m−CN¥103.0m−CN¥10.0m
Free cash flow———CN¥66.0mCN¥60.0mCN¥2.0m—CN¥92.0m
Total assetsCN¥3.77bnCN¥3.70bnCN¥3.76bnCN¥3.84bnCN¥3.91bnCN¥3.72bnCN¥3.71bnCN¥3.93bn
Cash and short-term investments———CN¥1.14bnCN¥1.15bnCN¥871.0mCN¥1.00bnCN¥1.17bn
Debt———CN¥629.4mCN¥684.2mCN¥597.8mCN¥575.6mCN¥700.4m
Shareholders' equityCN¥2.94bnCN¥2.83bnCN¥2.75bnCN¥2.69bnCN¥2.68bnCN¥2.68bnCN¥2.62bnCN¥2.60bn

Financial ratios

Data as of 18 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin69.8%67.9%65.0%63.1%65.4%63.1%—
Operating margin22.8%23.1%23.5%31.7%33.2%33.9%—
Net margin21.0%19.2%20.4%27.4%28.5%27.1%—
Return on equity8.0%8.5%10.9%20.1%18.9%16.6%—
Return on assets5.9%6.0%7.4%13.6%12.7%11.3%—
Free cash flow yield12.6%12.2%12.7%15.2%12.7%6.5%—
Revenue growth-9.7%-14.9%-24.8%30.0%24.8%16.0%—
Earnings growth-1.3%-20.1%-43.9%25.0%30.9%-10.3%—
Current ratio2.69x1.98x2.20x2.50x2.91x3.22x—
Debt to equity—0.22x0.25x0.22x0.23x0.21x0.06x
Equity ratio73.3%70.6%67.9%67.5%67.1%68.1%—
Interest coverage19.83x17.44x18.44x33.66x29.15x53.03x—
R&D as a share of sales15.0%15.6%15.9%12.3%11.7%10.6%—
Buybacks as a share of market value9.1%-1.6%-0.8%4.5%-5.8%3.1%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-16.7%-1.3%14.3%
Operating income-23.0%-7.4%8.7%
Net income-23.8%-6.3%7.7%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin68.8%65.9%65.4%68.7%
Operating margin23.2%25.6%27.9%31.6%
Net margin20.0%22.6%24.3%27.5%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings17.919.020.012.618.928.617.820.341.0
Price to sales3.73.64.13.55.47.86.37.416.3

Dividends and splits

Per share, in the currency the company pays

Paid for 8 years. Last went ex-dividend on 18 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.150.180.190.400.340.1840.2040.149
  • 7-for-5 split · 8 Jun 2022
  • 7-for-5 split · 23 Jun 2021
  • 7-for-5 split · 21 May 2019
  • 7-for-5 split · 1 Jun 2018

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.